Ayako Shiono

1.2k total citations
59 papers, 783 citations indexed

About

Ayako Shiono is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Ayako Shiono has authored 59 papers receiving a total of 783 indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 14 papers in Epidemiology. Recurrent topics in Ayako Shiono's work include Cancer Immunotherapy and Biomarkers (29 papers), Lung Cancer Treatments and Mutations (29 papers) and Lung Cancer Research Studies (18 papers). Ayako Shiono is often cited by papers focused on Cancer Immunotherapy and Biomarkers (29 papers), Lung Cancer Treatments and Mutations (29 papers) and Lung Cancer Research Studies (18 papers). Ayako Shiono collaborates with scholars based in Japan, United States and Canada. Ayako Shiono's co-authors include Hiroshi Kagamu, Kyoichi Kaira, Ou Yamaguchi, Kunihiko Kobayashi, Yu Miura, Kosuke Hashimoto, Atsuto Mouri, Yoshitake Murayama, Fuyumi Nishihara and Hisao Imai and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Ayako Shiono

53 papers receiving 780 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ayako Shiono Japan 15 605 389 185 78 76 59 783
Atsuto Mouri Japan 16 520 0.9× 385 1.0× 86 0.5× 58 0.7× 51 0.7× 72 677
Ou Yamaguchi Japan 19 910 1.5× 677 1.7× 207 1.1× 87 1.1× 132 1.7× 88 1.1k
Yosuke Kawashima Japan 11 605 1.0× 339 0.9× 112 0.6× 74 0.9× 77 1.0× 41 721
Hayato Kawachi Japan 12 549 0.9× 435 1.1× 88 0.5× 46 0.6× 92 1.2× 35 711
Aliyah Pabani Canada 13 629 1.0× 533 1.4× 82 0.4× 62 0.8× 80 1.1× 32 814
Mary Kate Kasler United States 6 620 1.0× 191 0.5× 172 0.9× 135 1.7× 76 1.0× 8 713
Joshua E. Reuss United States 13 370 0.6× 257 0.7× 51 0.3× 30 0.4× 124 1.6× 54 521
Jumpei Kashima Japan 13 233 0.4× 311 0.8× 45 0.2× 76 1.0× 78 1.0× 41 566
Mikihiro Kohno Japan 14 331 0.5× 306 0.8× 133 0.7× 18 0.2× 143 1.9× 67 633
J.M. Sánchez-Torres Spain 13 614 1.0× 428 1.1× 99 0.5× 39 0.5× 150 2.0× 21 772

Countries citing papers authored by Ayako Shiono

Since Specialization
Citations

This map shows the geographic impact of Ayako Shiono's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ayako Shiono with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ayako Shiono more than expected).

Fields of papers citing papers by Ayako Shiono

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ayako Shiono. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ayako Shiono. The network helps show where Ayako Shiono may publish in the future.

Co-authorship network of co-authors of Ayako Shiono

This figure shows the co-authorship network connecting the top 25 collaborators of Ayako Shiono. A scholar is included among the top collaborators of Ayako Shiono based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ayako Shiono. Ayako Shiono is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Imai, Hisao, Ayako Shiono, Kosuke Hashimoto, et al.. (2025). Efficacy and Safety of Amrubicin Monotherapy After Chemoradiotherapy in Patients With Relapsed Limited Disease Small-cell Lung Cancer. Anticancer Research. 45(2). 733–741. 1 indexed citations
2.
Endo, Satoshi, Hisao Imai, Atsuto Mouri, et al.. (2025). Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 151(1). 43–43. 2 indexed citations
3.
Kaira, Kyoichi, Hisao Imai, Ayako Shiono, et al.. (2025). Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapy. Translational Lung Cancer Research. 14(5). 1569–1581. 1 indexed citations
4.
Ito, Koki, Kyoichi Kaira, Ou Yamaguchi, et al.. (2024). Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy. Oncology Letters. 27(3). 110–110. 4 indexed citations
5.
6.
Hashimoto, Kosuke, Kyoichi Kaira, Hisao Imai, et al.. (2024). Clinical significance of visual cardiac 18F-FDG uptake in advanced non-small cell lung cancer. Cancer Imaging. 24(1). 157–157. 1 indexed citations
7.
Endo, Satoshi, Hisao Imai, Ayako Shiono, et al.. (2024). The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer. Oncology. 103(2). 1–11.
8.
Yamaguchi, Ou, Norimitsu Kasahara, Hiroshi Soda, et al.. (2023). Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib. Scientific Reports. 13(1). 20848–20848. 5 indexed citations
9.
Kaira, Kyoichi, Hisao Imai, Atsuto Mouri, et al.. (2023). Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR‐major mutant NSCLC receiving osimertinib. Thoracic Cancer. 14(29). 2950–2961. 3 indexed citations
10.
Kaira, Kyoichi, Ou Yamaguchi, Tomonori Kawasaki, et al.. (2023). Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer. Discover Oncology. 14(1). 6–6. 16 indexed citations
11.
Kagamu, Hiroshi, Shigehisa Kitano, Ou Yamaguchi, et al.. (2022). Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy. Cancer Research. 82(24). 4641–4653. 27 indexed citations
12.
Mouri, Atsuto, Kyoichi Kaira, Ou Yamaguchi, et al.. (2021). Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. Frontiers in Oncology. 11. 610952–610952. 11 indexed citations
13.
Imai, Hisao, Ou Yamaguchi, Kosuke Hashimoto, et al.. (2021). Efficacy and Safety of Anti-Programed Death-1 Blockade in Previously Treated Large-Cell Neuroendocrine Carcinoma. Chemotherapy. 66(3). 65–71. 4 indexed citations
14.
15.
Yamaguchi, Ou, Kyoichi Kaira, Kosuke Hashimoto, et al.. (2020). Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%. Scientific Reports. 10(1). 14990–14990. 24 indexed citations
16.
Kagamu, Hiroshi, Shigehisa Kitano, Ou Yamaguchi, et al.. (2019). CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy. Cancer Immunology Research. 8(3). 334–344. 169 indexed citations
17.
Yamaguchi, Ou, Kyoichi Kaira, Atsuto Mouri, et al.. (2019). Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation. Cancer Chemotherapy and Pharmacology. 83(5). 817–825. 12 indexed citations
18.
Itô, Masayuki, Kazuyuki Nakagome, Hiromitsu Ohta, et al.. (2017). Elderly-onset hereditary pulmonary alveolar proteinosis and its cytokine profile. BMC Pulmonary Medicine. 17(1). 40–40. 11 indexed citations
19.
Hirama, Takashi, et al.. (2013). A Case of Lung Paragonimiasis Superinfection with Hookworm Presenting Difficulty in Discrimination. Kansenshogaku zasshi. 87(6). 756–760.
20.
Nakano, Shintaro, Fumiko Kimura, Nael F. Osman, et al.. (2013). Improved Myocardial Strain Measured by Strain-Encoded Magnetic Resonance Imaging in a Patient With Cardiac Sarcoidosis. Canadian Journal of Cardiology. 29(11). 1531.e9–1531.e11. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Atsuto Mouri Breakdown of academic impact, for papers by Ou Yamaguchi Breakdown of academic impact, for papers by Yosuke Kawashima Breakdown of academic impact, for papers by Hayato Kawachi Breakdown of academic impact, for papers by Aliyah Pabani Breakdown of academic impact, for papers by Mary Kate Kasler Breakdown of academic impact, for papers by Joshua E. Reuss Breakdown of academic impact, for papers by Jumpei Kashima Breakdown of academic impact, for papers by Mikihiro Kohno Breakdown of academic impact, for papers by J.M. Sánchez-Torres
Rankless by CCL
2026